Andrew Bellinger is Chief Scientific Officer of Verve Therapeutics, Inc.. Currently has a direct ownership of 42,629 shares of VERV, which is worth approximately $193,961. The most recent transaction as insider was on Dec 14, 2022, when has been sold 36,000 shares (Common Stock) at a price of $2.87 per share, resulting in proceeds of $103,320. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 42.6K
0% 3M change
0% 12M change
Total Value Held $193,961

Andrew Bellinger Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 14 2022
BUY
Exercise of conversion of derivative security
$103,320 $2.87 p/Share
36,000 Added 45.78%
42,629 Common Stock
Dec 01 2022
SELL
Open market or private sale
$19,851 $22.95 p/Share
865 Reduced 11.54%
6,629 Common Stock
Oct 28 2022
SELL
Open market or private sale
$399,000 $39.9 p/Share
10,000 Reduced 60.14%
6,629 Common Stock
Oct 28 2022
BUY
Exercise of conversion of derivative security
$14,800 $1.48 p/Share
10,000 Added 37.55%
16,629 Common Stock
Sep 23 2022
SELL
Open market or private sale
$2,124,000 $35.4 p/Share
60,000 Reduced 90.05%
6,629 Common Stock
Sep 23 2022
BUY
Exercise of conversion of derivative security
$88,800 $1.48 p/Share
60,000 Added 56.27%
46,629 Common Stock
Jul 20 2022
SELL
Open market or private sale
$698,000 $34.9 p/Share
20,000 Reduced 75.11%
6,629 Common Stock
Jul 20 2022
BUY
Exercise of conversion of derivative security
$27,800 $1.39 p/Share
20,000 Added 42.89%
26,629 Common Stock
Jul 13 2022
SELL
Open market or private sale
$249,000 $24.9 p/Share
10,000 Reduced 60.14%
6,629 Common Stock
Jul 13 2022
BUY
Exercise of conversion of derivative security
$14,800 $1.48 p/Share
10,000 Added 37.55%
16,629 Common Stock
Dec 22 2021
SELL
Open market or private sale
$576,900 $38.46 p/Share
15,000 Reduced 75.0%
5,000 Common Stock
Dec 22 2021
BUY
Exercise of conversion of derivative security
$22,200 $1.48 p/Share
15,000 Added 42.86%
20,000 Common Stock
Jun 21 2021
BUY
Open market or private purchase
$95,000 $19.0 p/Share
5,000 Added 50.0%
5,000 Common Stock
AB

Andrew Bellinger

Chief Scientific Officer
Cambridge, MA

Track Institutional and Insider Activities on VERV

Follow Verve Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VERV shares.

Notify only if

Insider Trading

Get notified when an Verve Therapeutics, Inc. insider buys or sells VERV shares.

Notify only if

News

Receive news related to Verve Therapeutics, Inc.

Track Activities on VERV